Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vadadustat - Akebia Therapeutics

Next Previous
Drug Profile

Vadadustat - Akebia Therapeutics

Alternative Names: AKB-6548; MT 6548; PG 1016548; VAFSEO; Vafseo

Latest Information Update: 23 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Developer Akebia Therapeutics; MEDICE; Otsuka Pharmaceutical; Tanabe Pharma Corporation
  • Class Acetic acids; Amides; Antianaemics; Antivirals; Chlorobenzenes; Chlorophenols; Pyridines; Small molecules; Urologics
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase II Renal failure; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 15 Sep 2026 The State Institute for Drug Control (SÚKL) of Czech Republic issues a positive reimbursement decision for vadadustat in Anaemia
  • 12 Aug 2026 Akebia Therapeutics completes a phase III trial in Anemia in USA (PO) (NCT06901505)
  • 30 Jun 2026 Adverse events data from a phase III trial in Anaemia released by Akebia Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top